美国信息技术与创新基金会2024中国在生物技术领域的创新能力如何研究报告英文版44页

itif.org How Innovative Is China in Biotechnology? SANDRA BARBOSU | AUGUST 2024 China used to be considered a laggard in biotech. But with a comprehensive national strategy and extensive resources now supporting the industry, it is becoming more innovative. In fact, several indicators suggest it is narrowing the innovation gap with global leaders in the West. KEY TAKEAWAYS  Recent Chinese government policies have emphasized domestic biotech innovation. A new national strategy has been crucial to the sector’s growth.  Several factors are spurring growth, including subsidies, financial incentives, science parks, start-up incubators, talent recruitment schemes, public-private partnerships, and reforms to expedite drug review and enhance IP protection.  Indicators suggest Chinese biotech is becoming more innovative. For example, the U.S. FDA approved three new Chinese drugs in 2023.  China’s out-licensing deals grew from 15 in 2019 to 33 in 2023, with the largest increase being in